Iovance Biotherapeutics, Inc. (IOVA) is a company that is currently trading at $2.3500 as of January 13th. Despite its low stock price, there is a bullish thesis on IOVA that has been shared by u/DebtFit2132 on r/biotech_stocks. This thesis highlights the company’s high-risk strategy of funding operations through equity dilution rather than accepting a distressed valuation. Management and influential insiders at IOVA believe in the long-term potential of the Tumor Infiltrating Lymphocyte platform, particularly in treating lung cancer. They see this as a potential multibillion-dollar opportunity.
The confidence of insiders in the company’s future prospects has led to a willingness to sell stock to maintain operations rather than accept a buyout offer at the current low prices. This has created a disconnect between the market perception of IOVA as a failed biotech and the internal expectations of the company’s value. Insiders, such as Wayne Rothbaum, have a higher estimated cost basis of around $9.00, which further complicates any potential acquisition offers.
The valuation gap between market perception and internal expectations has essentially frozen standard acquisition activity for IOVA. Any potential buyout offer would need to reflect the higher internal valuation held by the board members and long-term holders. This may require a creative structure, such as contingent value rights, to bridge the gap between the current share price and the company’s bullish view of future value.
Operationally, IOVA has a rare and defensible asset in Amtagvi that competitors cannot easily replicate. However, the company’s gross margins of 24% to 43% are significantly lower than the typical 80% to 95% seen in commercial oncology drugs. This makes the standalone model cash-intensive and raises concerns about the company’s profitability in the long run.
For a potential acquirer, the key question is whether superior manufacturing scale can improve IOVA’s margins to 70% or higher. If successful, an acquisition could be transformative for the company. However, if margins do not improve, Amtagvi risks becoming a revenue drain on returns.
In conclusion, the bullish thesis on IOVA emphasizes the high-risk, high-reward nature of the company, its acquisition potential, and the strong internal conviction of management and insiders. While the stock price may currently be low, the long-term prospects for IOVA could be significant if the company can overcome its operational challenges and realize the full potential of its Tumor Infiltrating Lymphocyte platform.
